Acquisition by Pamela Stephenson of 35000 shares of Zynerba Pharmaceuticals subject to Rule 16b-3

Please consider monitoring Zynerba Pharmaceuticals on a daily basis if you are holding a position in it. Zynerba Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Zynerba Pharmaceuticals stock to be traded above the $1 level to remain listed. If Zynerba Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Zynerba Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Zynerba Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Zynerba Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Zynerba Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Zynerba Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Zynerba Pharmaceuticals's total debt and its cash.